A 62-year-old man from Delhi presents with bone pain and fatigue for 3 months. Serum calcium is 11.2 mg/dL, creatinine is 2.1 mg/dL, and hemoglobin is 9.2 g/dL. Serum protein electrophoresis shows an M-spike. Bone marrow biopsy confirms 30% plasma cells. What is the most appropriate next step in management?

Question

A 62-year-old man from Delhi presents with bone pain and fatigue for 3 months. Serum calcium is 11.2 mg/dL, creatinine is 2.1 mg/dL, and hemoglobin is 9.2 g/dL. Serum protein electrophoresis shows an M-spike. Bone marrow biopsy confirms >30% plasma cells. What is the most appropriate next step in management?

Accepted Answer

D. Perform cytogenetic analysis and fluorescence in situ hybridization (FISH) on bone marrow to assess risk stratification. ## Risk Stratification Before Treatment Initiation **Key Point:** Cytogenetic and FISH analysis of bone marrow plasma cells is mandatory BEFORE starting therapy in newly diagnosed multiple myeloma (MM) to determine prognosis and guide treatment intensity. ### Why Cytogenetics/FISH is the Next Step Once MM diagnosis is confirmed (>30% bone marrow plasma cells + CRAB criteria met), the immediate next step is **risk stratification** using: 1. **Cytogenetics (conventional karyotyping)** — identifies hyperdiploidy, translocations 2. **FISH** — detects high-risk lesions: - `t(4;14)` — poor prognosis - `t(14;16)` — poor prognosis - `del(17p)` — very high risk - `del(13q)` — intermediate risk **High-Yield:** High-risk cytogenetics (del(17p), t(4;14), t(14;16)) mandate **proteasome inhibitor (PI)–based or immunomodulatory drug (IMiD)–based induction**, whereas standard-risk disease can use various regimens. ### Management Sequence in MM ```mermaid flowchart TD A[MM diagnosis confirmed
CRAB + BM plasma cells]:::outcome --> B[Cytogenetics/FISH analysis]:::action B --> C{Risk stratification}:::decision C -->|High-risk| D[PI + IMiD ± corticosteroid]:::action C -->|Standard-risk| E[Flexible induction options]:::action D --> F[Assess response at 4 cycles]:::action E --> F F --> G[Stem cell transplant consideration]:::decision ``` ### Why Other Options Are Premature | Option | Why Not Next | Correct Timing | |--------|-------------|----------------| | **Bortezomib immediately** | Cannot choose therapy without risk stratification; may over/under-treat | After FISH results | | **Hydration + allopurinol** | Supportive care is parallel, not sequential; renal impairment is part of CRAB but doesn't delay cytogenetics | Concurrent with workup | | **PET scan** | Whole-body imaging is not standard for MM staging; skeletal survey or low-dose CT suffices | Not routine in MM | **Clinical Pearl:** Renal impairment (Cr 2.1) is a CRAB criterion and does NOT delay cytogenetic testing — both proceed in parallel during the diagnostic phase. **Mnemonic — CRAB Criteria:** **C**alcium (>11.5), **R**enal insufficiency (Cr >2), **A**nemia (Hb <10), **B**one lesions (lytic). This patient has C, R, and A. [cite:Harrison 21e Ch 186]

Answer

A. Perform whole-body positron emission tomography (PET) scan to stage bone disease

Answer

B. Initiate bortezomib-based induction therapy immediately

Answer

C. Start hydration and allopurinol; defer chemotherapy until renal function stabilizes

Explanation

Risk Stratification Before Treatment Initiation

Why Cytogenetics/FISH is the Next Step

Management Sequence in MM

Why Other Options Are Premature

Practice similar questions

Join our NEET PG community

Option	Why Not Next	Correct Timing
Bortezomib immediately	Cannot choose therapy without risk stratification; may over/under-treat	After FISH results
Hydration + allopurinol	Supportive care is parallel, not sequential; renal impairment is part of CRAB but doesn't delay cytogenetics	Concurrent with workup
PET scan	Whole-body imaging is not standard for MM staging; skeletal survey or low-dose CT suffices	Not routine in MM